Structure Therapeutics’ stock soared toward an 18-month high in early Monday trading, after mid-stage data for its oral daily GLP-1 receptor appeared comparable to that of one of Eli Lilly’s ...

Vibhas is a Software Development Manager at Amazon with over 12 years of industry experience in large scale distributed systems, databases and cloud native applications. Vibhas is a Software ...

Recursion’s oral drug candidate for cerebral cavernous malformation showed no improvements in patient- or physician-reported outcomes at 12 months. The biotech will engage with the FDA to determine ...

Recursion Pharmaceuticals (NASDAQ:RXRX) led a selloff among AI-driven biotechs on Tuesday after the company, backed by chipmaker Nvidia (NASDAQ:NVDA), announced initial results from a Phase 2 trial ...

(Reuters) -Nvidia-backed Recursion Pharmaceuticals said on Tuesday its experimental drug to treat a rare brain-related condition was safe and tolerable in a mid-stage study, but showed mixed results ...

I am a developer of open source. I have been an SRE for the last 10 years, of which I have been a team leader 5 years. I am a developer of open source. I have been an ...